Table 3. Comparison of patients with and without discordance.
Variables | Patients without discordance(n = 148, 91.9%) | Patients with discordance(n = 13, 8.1%) | P value |
Demographic variables | |||
Age (years) | 49 (18–81) | 52 (35–70) | NS |
Male gender | 95 (64.2) | 7 (53.8) | NS |
Body mass index (kg/m2) | 24.4 (14.3–34.3) | 24.5 (21.6–29.8) | NS |
Diabetes mellitus | 23 (15.5) | 5 (38.5) | NS |
Etiology, NAFLD/HBV/HCV/Others | 64 (43.9)/45 (30.4)/26 (17.6)/12 (8.1) | 7 (53.8)/4 (30.8)/2 (15.4)/0 (0.0) | NS |
Biochemical parameters | |||
Aspartate aminotransferase (IU/L) | 46.1±37.1 | 34.5±21.2 | NS |
Alanine aminotransferase (IU/L) | 50.9±45.0 | 36.6±25.8 | NS |
Serum albumin (g/dL) | 4.1±0.5 | 4.2±0.4 | NS |
Fasting glucose (mg/mL) | 108.2±34.6 | 124.0±39.5 | NS |
Total cholesterol (mg/mL) | 171.5±40.9 | 180.1±36.0 | NS |
Triglycerides (mg/mL) | 126.2±60.4 | 153.7±54.9 | NS |
Liver biopsy | |||
Fibrosis stage | |||
F0–2/F3–4 | 99 (66.9)/49 (33.1) | 10 (76.9)/3 (23.1) | NS |
Activity grade | |||
A0–2/A3 | 114 (77.0)/34 (23.0) | 9 (69.2)/4 (30.8) | NS |
Steatosis | |||
S0–2/S3 | 144 (97.3 )/4 (2.7) | 11 (84.6)/2 (15.4) | 0.021 |
Biopsy length (cm) | 18.2 (16.4–24.2) | 18.6 (16.1–23.5) | NS |
Liver stiffness measurement | |||
Liver stiffness value (kPa) | 8.2 (2.9–75.0) | 7.4 (3.0–17.5) | NS |
Interquartile range (kPa) | 1.0 (0.1–14.0) | 1.5 (0.4–2.6) | NS |
IQR/M | 0.12 (0.01–0.35) | 0.15 (0.06–0.26) | NS |
Controlled attenuation parameter | |||
Controlled attenuation parameter value (dB/m) | 250 (149–400) | 327 (230–345) | 0.010 |
Interquartile range (dB/m) | 29.0 (6–72) | 30.0 (15–76) | NS |
IQR/MCAP | 0.12 (0.02–0.28) | 0.10 (0.05–0.33) | NS |
Variables are expressed as median (range) or n (%).
NS, not significant; NAFLD, non-alcoholic fatty liver disease; HBV, hepatitis B; HCV, hepatitis C; kPa, kilopascal; IQR/M, interquartile range/median liver stiffness value; CAP, controlled attenuation parameter; IQR/MCAP, interquartile range/median of CAP value.